Participant flow12

How many started, completed or left each group, period by period.

1 to 12 of 12

Period	Milestone	Group	Participants
Study Period	STARTED	Afamelanotide	48
Study Period	STARTED	Placebo	45
Study Period	COMPLETED	Afamelanotide	45
Study Period	COMPLETED	Placebo	42
Study Period	NOT COMPLETED	Afamelanotide	3
Study Period	NOT COMPLETED	Placebo	3
Safety Follow-Up Period	STARTED	Afamelanotide	45
Safety Follow-Up Period	STARTED	Placebo	42
Safety Follow-Up Period	COMPLETED	Afamelanotide	44
Safety Follow-Up Period	COMPLETED	Placebo	40
Safety Follow-Up Period	NOT COMPLETED	Afamelanotide	1
Safety Follow-Up Period	NOT COMPLETED	Placebo	2

Source ClinicalTrials.govtrials-2026-11-12-0.5.0

Sources 3

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ClinicalTrials.govNo license stated
NIH RePORTER's clinical studies and project filesPublic domain

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ClinicalTrials.govnone stated
NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Twenty rows a page, as JSON. No key.

GET https://conductscience.org/api/trials/v1/NCT01605136/flow